Диссертация (1174200), страница 48
Текст из файла (страница 48)
– № 2. – P. 105-108.29490. Berry R.E. Free-floating deep venous thrombosis. A retrospective analysis. / R.E.Berry, J.E. George, W.A. Shaver // Annals of surgery. – 1990. – Т. 211. – № 6. –P. 719-73.91. Beyer-Westendorf J. Rates, management, and outcome of rivaroxaban bleeding indaily care: results from the Dresden NOAC registry / J. Beyer-Westendorf [et al.] //Blood. – 2014. – Т. 124. – № 6. – P. 955-962.92. Borris L.C. Thromboprophylaxis with low molecular weight heparin after majororthopaedic surgery is cost effective / L.C. Borris, M.R.
Lassen // Drugs. – 1996. –Т. 52. – № 7. – P. 42-46.93. Böttiger B.W. Efficacy and safety of thrombolytic therapy after initiallyunsuccessful cardiopulmonary resuscitation: a prospective clinical trial / B.W.Böttiger [et al.] // The Lancet. – 2001.
– Т. 357. – № 9268. – P. 1583-1585.94. Boutitie F. Influence of preceding length of anticoagulant treatment and initialpresentation of venous thromboembolism on risk of recurrence after stoppingtreatment: analysis of individual participants’ data from seven trials / F. Boutitie[et al.] // Bmj.–2011.– Т. 342.–P. 1-9.– Modeof access:https://doi.org/10.1136/bmj.d3036.95. Brown J.D. Vena cava filter retrieval rates and factors associated with retrieval in alarge US cohort / J.D. Brown [et al.] // Journal of the American Heart Association.–2017.–Т. 6.–№ 9.–P. 1-11.–Modeofaccess:http://jaha.ahajournals.org/content/6/9/e006708.96. Brunson A. Inferior vena cava filters in patients with cancer and venousthromboembolism (VTE): patterns of use and outcomes / A. Brunson [et al.] //Thrombosis research.
– 2016. – Т. 140. – P. S132-S141.97. Buller H.R. Oral rivaroxaban for the treatment of symptomatic pulmonaryembolism / H.R. Buller [et al.] // New England Journal of Medicine. – 2012. –Т. 366. – № 14. – P. 1287-1297.98. Buller H.R. Low-molecular-weight heparin in the treatment of patients withvenous thromboembolism. The Columbus Investigators / H.R. Buller, M. Gent,A.S. Gallus // N Engl J Med. – 1997. – Т. 337. – № 10. – P. 657-662.29599.
Campbell N.R. Aging and heparin-related bleeding / N.R. Campbell [et al.] //Archives of internal medicine. – 1996. – Т. 156. – № 8. – P. 857-860.100. CarrierM.Systematicreview: case-fatality ratesof recurrentvenousthromboembolism and major bleeding events among patients treated for venousthromboembolism / M. Carrier [et al.] // Annals of internal medicine. – 2010. –Т. 152. – № 9.
– P. 578-589.101. Casey E.T. Treatment of acute iliofemoral deep vein thrombosis / E.T. Casey [etal.] // Journal of vascular surgery. – 2012. – Т. 55. – № 5. – P. 1463-1473.102. Casian D. Extraluminal venous interruption for free-floating thrombus in the deepveins of lower limbs / D. Casian, E. Gutsu, V. Culiuc // Chirurgia (Bucur). – 2010.– Т. 105. – № 3.
– P. 361-364.103. Chai‐Adisaksopha C. Mortality outcomes in patients receiving direct oralanticoagulants: a systematic review and meta‐analysis of randomized controlledtrials / C. Chai‐Adisaksopha [et al.] // Journal of Thrombosis and Haemostasis. –2015. – Т. 13. – № 11. – P. 2012-2020.104. Charbonnier B.A. Comparison of a once daily with a twice daily subcutaneous lowmolecular weight heparin regimen in the treatment of deep vein thrombosis / B.A.Charbonnier [et al.] // Thrombosis and haemostasis. – 1998.
– Т. 79. – № 5. –P. 897-901.105. Chiou A.C. Intravascular ultrasound-guided bedside placement of inferior venacava filters / A.C. Chiou // Seminars in vascular surgery. – Elsevier. – 2006. –Т. 19. – P. 150-154.106. Cohen A.T. Venous thromboembolism (VTE) in Europe / A.T. Cohen [et al.] //Thrombosis and haemostasis.
– 2007. – Т. 98. – № 10. – P. 756-764.107. Cohen A.T. Comparison of the novel oral anticoagulants apixaban, dabigatran,edoxaban, and rivaroxaban in the initial and long-term treatment and prevention ofvenous thromboembolism: systematic review and network meta-analysis / A.T.Cohen [et al.] // PLoS One. – 2015.
– Т. 10. – № 12. – P. 1-14.296108. Coleman C.I. Effectiveness and safety of rivaroxaban versus warfarin in patientswith provoked venous thromboembolism / C.I. Coleman [et al.] // Journal ofthrombosis and thrombolysis. – 2018. – Т. 46. – № 3. – P. 339-345.109. Coleman C.I. Impact of Prolonged Anticoagulation with Rivaroxaban on ProvokedVenous Thromboembolism Recurrence: IMPROVE-VTE / C.I. Coleman [et al.] //The American journal of medicine. – 2019. – Т.
132. – № 4. – P. 498-504.110. Coquoz N. Multicentre observational screening survey for the detection of CTEPHfollowing pulmonary embolism / N. Coquoz [et al.] // European respiratoryjournal.–2018.–Т. 51.–№ 4.–Modeofaccess:https://doi.org/10.1183/13993003.02505-2017.111.
Couturaud F. Six months vs extended oral anticoagulation after a first episode ofpulmonary embolism: the PADIS-PE randomized clinical trial / F. Couturaud [etal.] // Jama. – 2015. – Т. 314. – № 1. – P. 31-40.112. Das S.K. Low-molecular-weight heparin versus warfarin for prevention ofrecurrent venous thromboembolism: a randomized trial / S.K. Das [et al.] // Worldjournal of surgery.
– 1996. – Т. 20. – № 5. – P. 521-527.113. Dawwas G.K. Effectiveness and safety of apixaban versus rivaroxaban forprevention of recurrent venous thromboembolism and adverse bleeding events inpatients with venous thromboembolism: a retrospective population-based cohortanalysis / G.K. Dawwas [et al.] // The Lancet Haematology. – 2019. – Т. 6. – № 1.– P. 20-28.114. Decousus H. A clinical trial of vena caval filters in the prevention of pulmonaryembolism in patients with proximal deep-vein thrombosis / H. Decousus [et al.] //New England Journal of Medicine.
– 1998. – Т. 338. – № 7. – P. 409-416.115. Dentali F. Prevalence and clinical history of incidental, asymptomatic pulmonaryembolism: a meta-analysis / F. Dentali [et al.] // Thrombosis research. – 2010. –Т. 125. – № 6. – P. 518-522.116. Dentali F. Time trends and case fatality rate of in-hospital treated pulmonaryembolism during 11 years of observation in Northwestern Italy / F.
Dentali [et al.]// Thrombosis and haemostasis. – 2016. – Т. 116. – № 2. – P. 399-405.297117. Desai J. Gastrointestinal bleeding with the new oral anticoagulants–defining theissues and the management strategies / J. Desai [et al.] // Thrombosis andhaemostasis. – 2013. – Т. 110. – № 08.
– P. 205-212.118. Desai K.R. Defining prolonged dwell time: when are advanced inferior vena cavafilter retrieval techniques necessary? an analysis in 762 procedures / K.R. Desai [etal.] // Circulation: Cardiovascular Interventions. – 2017. – Т. 10. – № 6. – P. 1-5.119. Deso S.E. Evidence-based evaluation of inferior vena cava filter complicationsbased on filter type / S.E. Deso, I.A. Idakoji, W.T. Kuo // Seminars ininterventional radiology. – Thieme Medical Publishers, 2016. – Т.
33. – P. 093100.120. Di Nisio M. Direct thrombin inhibitors / M. Di Nisio, S. Middeldorp, H.R. Büller //New England Journal of Medicine. – 2005. – Т. 353. – № 10. – P. 1028-1040.121. Donaldson M.C. Thirty-year experience with surgical interruption of the inferiorvena cava for prevention of pulmonary embolism / M.C. Donaldson, L.S. Wirthlin,G.A. Donaldson // Annals of surgery. – 1980. – Т.
191. – № 3. – P. 367-372.122. Doyle D.J. Adjusted subcutaneous heparin or continuous intravenous heparin inpatients with acute deep vein thrombosis: a randomized trial / D.J. Doyle [et al.] //Annals of Internal Medicine. – 1987. – Т. 107. – № 4. – P. 441-445.123. Droege M.E. Effect of a dalteparin prophylaxis protocol using anti-factor Xaconcentrations on venous thromboembolism in high-risk trauma patients / M.E.Droege [et al.] // Journal of Trauma and Acute Care Surgery.
– 2014. – Т. 76. –№ 2. – P. 450-456.124. DuG.-C.Catheter-directedthrombolysisplusanticoagulationversusanticoagulation alone in the treatment of proximal deep vein thrombosis-a metaanalysis / G.-C. Du, M.-C. Zhang, J.-C. Zhao // Vasa. – 2015. – Т. 44. – № 3. –P. 195-202.125. Dueppers P. Surgical management of iliofemoral vein thrombosis duringpregnancy and the puerperium / P. Dueppers [et al.] // Journal of Vascular Surgery:Venous and Lymphatic Disorders. – 2016. – Т. 4. – № 4.
– P. 392-399.298126. Duffett L.D. Outcomes of patients requiring insertion of an inferior vena cavafilter: a retrospective observational study / L.D. Duffett [et al.] // BloodCoagulation & Fibrinolysis. – 2014. – Т. 25. – № 3. – P. 266-271.127. Duszak Jr R. Placement and removal of inferior vena cava filters: national trends inthe medicare population / R. Duszak Jr [et al.] // Journal of the American Collegeof Radiology. – 2011. – Т. 8.
– № 7. – P. 483-489.128. Egermayer P. Value of Anticoagulants in the Treatment of Pulmonary Embolism:A Discussion Paper / P. Egermayer // Journal of the Royal Society of Medicine. –1981. – Т. 74. – № 9. – P. 675-681.129. Eggers M.D. Pilot in vivo study of an absorbable polydioxanone vena cava filter /M.D. Eggers [et al.] // Journal of Vascular Surgery: Venous and LymphaticDisorders. – 2015. – Т. 3. – № 4. – P. 409-420.130. Eichinger S. Clinical perspective / S. Eichinger [et al.] // Circulation. – 2010. –Т. 121.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
